CKD Prediction in HIV+ Patients

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
ckd risk percentage
—percent
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–5
  • Moderate Risk5–15
  • High Risk15–100
Direct Clinical Answer

The CKD Prediction in HIV+ Patients calculates estimating glomerular filtration rate (eGFR), staging renal disease, and adjusting drug clearances. Key inputs include age category. Scores guide adjusting renal medication clearance, coordinating nephrology follow-up, or planning renal replacement therapy. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Determines likelihood of HIV patients developing CKD in the next 5 years, whether they take tenofovir or not

Clinical Indication

The CKD Prediction in HIV+ Patients is indicated for bedside clinical practice to support Determines likelihood of HIV patients developing CKD in the next 5 years, whether they take tenofovir or not. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute kidney injury (AKI), chronic kidney disease stages 1-5, or acid-base and fluid-electrolyte disturbances. Clinical application is indicated across Nephrology clinics, hemodialysis units, acute inpatient renal services, and metabolic wards.

Limitations & Contraindications

eGFR estimation equations assume steady-state serum creatinine and become unreliable during unstable AKI, amputations, or extremes of muscle mass.

Clinical Pearls & Action Plan

Serum creatinine lags behind acute reductions in glomerular filtration; monitor hourly urine output and consider cystatin C in evolving AKI. Guideline pearl: Regular monitoring of kidney function recommended regardless of risk score.

Formula & Variables:

Sum of risk factor points: Age (0-6) + Glucose >140 (2) + SBP >140 (1) + Hypertension (2) + Triglycerides >200 (1) + Proteinuria (2) + CD4+ <200 (1). 5-year CKD risk based on total score and tenofovir use status.

Input Parameters

NameTypeRequiredDescription
age_categorystringYesPatient age category(years)
glucose_elevatedstringYesGlucose > 140 mg/dL(mg/dL)
systolic_bp_elevatedstringYesSystolic blood pressure > 140 mmHg(mmHg)
hypertensionstringYesDiagnosis of hypertension
triglycerides_elevatedstringYesTriglycerides > 200 mg/dL(mg/dL)
proteinuriastringYesPresence of proteinuria
cd4_lowstringYesCD4+ count < 200 cells/µL(cells/µL)
tenofovir_usestringYesCurrent or planned tenofovir (TDF) use

Score Interpretation & Guidance

RangeStageDescription
0–5Low RiskLow risk for CKD development
5–15Moderate RiskModerate risk for CKD development
15–100High RiskHigh risk for CKD development

Evidence-Based References (EBM)

  • Scherzer R, Gandhi M, Estrella MM, Tien PC, Deeks SG, Grunfeld C, Peralta CA, Shlipak MG. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS. 2014;28(9):1289-95.
  • Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D Study Group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015;12(3):e1001809.

Related calculators